Market Place
Sourcing Support
SAB BIO Announces Third Quarter 2024 Financial Results & Update
06 Nov 2024 //
GLOBENEWSWIRE
SAB BIO CEO To Participate In Fireside Chat At Cantor Healthcare Conference
13 Sep 2024 //
GLOBENEWSWIRE
SAB BIO Provides SAB-142 Clinical Trial Progress Update
09 Sep 2024 //
GLOBENEWSWIRE
SAB BIO To Present At European Diabetes Association Meeting
04 Sep 2024 //
GLOBENEWSWIRE
SAB BIO Announces Q2 2024 Results And Company Updates
08 Aug 2024 //
GLOBENEWSWIRE
SAB BIO Forms Clinical Advisory Board For SAB-142 Development
05 Aug 2024 //
GLOBENEWSWIRE
SAB BIO Appoints Lucy To as Chief Financial Officer
31 Jul 2024 //
GLOBENEWSWIRE
SAb Biotherapeutics Rebrands as SAB BIO
20 Jun 2024 //
GLOBENEWSWIRE
SAB to Present at the American Diabetes Association 84th Scientific Sessions
18 Jun 2024 //
GLOBENEWSWIRE
SAB Biotherapeutics Announces Departure of Chief Financial Officer
30 May 2024 //
GLOBENEWSWIRE
SAB`s gets US FDA clearance to proceed with ph 1 trial of SAB-142
23 May 2024 //
PHARMABIZ
FDA Clears SAB-142 Type 1 Diabetes Therapy IND
21 May 2024 //
GLOBENEWSWIRE
SAB Biotherapeutics Announces Q1 2024 Financials, Company Updates
20 May 2024 //
GLOBENEWSWIRE
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
06 May 2024 //
GLOBENEWSWIRE
SAB Biotherapeutics Provides SAB-142 Trial Update
16 Apr 2024 //
GLOBENEWSWIRE
SAB Biotherapeutics to Present at INNODIA Annual Meeting
08 Apr 2024 //
GLOBENEWSWIRE
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
04 Apr 2024 //
GLOBENEWSWIRE
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
29 Mar 2024 //
GLOBENEWSWIRE
SAB Announces Clinical Partnership with Naval Medical Research Center
25 Mar 2024 //
GLOBENEWSWIRE
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
23 Feb 2024 //
GLOBENEWSWIRE
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Conference
08 Feb 2024 //
GLOBENEWSWIRE
SAB Biotherapeutics Announces Executive Leadership Change
02 Feb 2024 //
GLOBENEWSWIRE
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
23 Jan 2024 //
GLOBENEWSWIRE
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
02 Jan 2024 //
GLOBENEWSWIRE
SAB Announces Commencement of the HUMAN Phase 1 Trial with SAB-142
29 Nov 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
20 Nov 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Announces Q3 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Announces Completion of $67.1 Million Financing
14 Nov 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
09 Nov 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
24 Oct 2023 //
GLOBENEWSWIRE
SAB Bio Receives Australian Approval to Commence Phase 1 Trial of SAB-142
19 Oct 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
05 Oct 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Announces Private Placement of up to $130 Million
02 Oct 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
21 Aug 2023 //
GLOBENEWSWIRE
SAB Presents Positive IND-Enabling GLP Toxicology Study for SAB-142
21 Jun 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data
30 May 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update
19 May 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
16 May 2023 //
GLOBENEWSWIRE
SAB Bio Announces First Publication of Promising Nonclinical Data for SAB-183
12 May 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Announces Progress on U.S. FDA™s Phased Review of Company™
09 May 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Presents Positive pH 1 & 2a Data for SAB-176
04 May 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
03 May 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Announces +ve Results from Ph3 Trial of SAB-185
26 Apr 2023 //
GLOBENEWSWIRE
SAB Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176
18 Apr 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176
13 Apr 2023 //
GLOBENEWSWIRE
SAB Bio Announces Appointment of Erick Lucera, CFA to Board of Directors
04 Apr 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Provides Company Update for Full Year 2022
31 Mar 2023 //
GLOBENEWSWIRE
SAB Bio CEO Eddie Sullivan to Present Next Generation Biologicsat Conference
19 Jan 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Receives an Additional $8.2M in Closeout of DoD Contract
18 Jan 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Concludes IND-Enabling GLP Toxicology Study for SAB-142
10 Jan 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics Novel DiversitAb™Platform Proven
05 Jan 2023 //
GLOBENEWSWIRE
SAB Biotherapeutics CMO Selected to Present at Biotech Showcase in San Francisco
15 Dec 2022 //
GLOBENEWSWIRE
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
07 Dec 2022 //
GLOBENEWSWIRE
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142
21 Nov 2022 //
GLOBENEWSWIRE
SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
15 Nov 2022 //
GLOBENEWSWIRE
SAB Biotherapeutics ‘Novel Biologic Therapeutics for Infectious Diseases’
08 Nov 2022 //
GLOBENEWSWIRE
SAB Biotherapeutics Presents Overview of DiversitAb™ Platform & Data Benefits
03 Nov 2022 //
GLOBENEWSWIRE
SAB Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
27 Oct 2022 //
GLOBENEWSWIRE
SAB Biotherapeutics Enters Exclusive Agreement with BioSolutions Inc.
27 Oct 2022 //
CONTRACTPHARMA
SAB Biotherapeutics Unveils New ISIRV OPTIONS XI Conference Validating SAB-176
28 Sep 2022 //
GLOBENEWSWIRE
